<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4241">
  <stage>Registered</stage>
  <submitdate>18/11/2013</submitdate>
  <approvaldate>18/11/2013</approvaldate>
  <nctid>NCT01995513</nctid>
  <trial_identification>
    <studytitle>Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients</studytitle>
    <scientifictitle>A Phase 4, Randomized, Double-blind, Placebo-controlled Study Of Continued Enzalutamide Treatment Beyond Progression In Patients With Chemotherapy-na√Øve Metastatic Castration-resistant Prostate Cancer</scientifictitle>
    <utrn />
    <trialacronym>PLATO</trialacronym>
    <secondaryid>2013-000722-54</secondaryid>
    <secondaryid>MDV3100-10</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Enzalutamide
Treatment: drugs - Abiraterone
Treatment: drugs - Placebo for Enzalutamide
Treatment: drugs - Prednisone

Experimental: Enzalutamide &amp; Abiraterone/prednisone - Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily

Active Comparator: Enzalutamide placebo &amp; Abiraterone/prednisone - Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily.


Treatment: drugs: Enzalutamide
160 mg by mouth once daily

Treatment: drugs: Abiraterone
1000 mg by mouth once daily

Treatment: drugs: Placebo for Enzalutamide
Sugar pill manufactured to mimic Enzalutamide 40 mg capsule

Treatment: drugs: Prednisone
5 mg by mouth twice daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS)</outcome>
      <timepoint>Every two months following randomization for up to 50 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to PSA Progression</outcome>
      <timepoint>Every two months following randomization for up to 50 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PSA Response</outcome>
      <timepoint>Every two months following randomization for up to 50 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR)</outcome>
      <timepoint>Every two months following randomization for up to 50 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of pain progression</outcome>
      <timepoint>Every two months following randomization for up to 50 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first use of subsequent antineoplastic therapy for prostate cancer</outcome>
      <timepoint>Every two months following randomization for up to 50 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life as assessed by the Functional Assessment of Cancer Therapy-Prostate (FACT-P)</outcome>
      <timepoint>Every two months following randomization for up to 50 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety as assessed by percentage of patients with any Adverse Event (AE), AE leading to Study Drug Discontinuation, AE leading to death, Serious Adverse Event (SAE), AE related to study drug, SAE related to study drug</outcome>
      <timepoint>Every two months following randomization for up to 50 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Men with metastatic castration-resistant prostate cancer

          -  Progressive disease on androgen deprivation therapy

          -  Patients must agree to continue androgen deprivation therapy with a GnRH
             agonist/antagonist throughout the study or have had a prior bilateral orchiectomy

          -  ECOG performance score = 1

          -  Estimated life expectancy of = 12 months</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone, or
             enzalutamide for the treatment of prostate cancer

          -  Prior participation in a clinical trial of an investigational agent that inhibits the
             androgen receptor or androgen synthesis (unless the treatment was placebo)

          -  History of brain metastasis, active leptomeningeal disease or seizure

          -  Severe cardiovascular or hepatic disease

          -  Pituitary or adrenal dysfunction</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>12/11/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>497</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Regional Imaging Border - Albury</hospital>
    <hospital>Terry White Chemist - Albury</hospital>
    <hospital>Concord Cancer Centre, Medical Oncology Department - Concord</hospital>
    <hospital>Macquarie University - North Ryde</hospital>
    <hospital>Port Macquarie Base Hospital,North Coast Cancer Institute - Port Macquarie</hospital>
    <hospital>North Shore Radiology and Nuclear Medicine - St Leonards</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Sydney Adventist Hospital - Sydney</hospital>
    <hospital>Northern NSW Local Health District - Tweed Heads</hospital>
    <hospital>Pharmacy Department, The Tweed Hospital - Tweed Heads</hospital>
    <hospital>Queensland Diagnostic Imaging - Tweed Heads</hospital>
    <hospital>Sydney Adventist Hospital - Wahroonga</hospital>
    <hospital>Regional Imaging Border - West Albury</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Icon Cancer Care Wesley - Auchenflower</hospital>
    <hospital>River City Pharmacy - APHS - Auchenflower</hospital>
    <hospital>Icon Cancer Care Chermside - Chermside</hospital>
    <hospital>Gold Coast Radiology PTY LTD - Hope Island</hospital>
    <hospital>Icon Cancer Care South Brisbane - South Brisbane</hospital>
    <hospital>Icon Cancer Care - South Brisbane</hospital>
    <hospital>Icon Cancer Foundation - South Brisbane</hospital>
    <hospital>South Coast Radiology - Tugun</hospital>
    <hospital>Adelaide Cancer Centre - Kurralta Park</hospital>
    <hospital>APHS Pharmacy - Kurralta Park</hospital>
    <hospital>Ashford Cancer Centre Research - Kurralta Park</hospital>
    <hospital>Cancer Care SA Pty Ltd - Kurralta Park</hospital>
    <hospital>Monash Medical Centre - Moorabbin campus - Bentleigh East</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Cabrini Health - Cabrini Hospital - Malvern</hospital>
    <hospital>Regional Imaging Border - Wangaratta</hospital>
    <hospital>Border Medical Oncology - Wodonga</hospital>
    <postcode>2640 - Albury</postcode>
    <postcode>2139 - Concord</postcode>
    <postcode>2019 - North Ryde</postcode>
    <postcode>2444 - Port Macquarie</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2076 - Sydney</postcode>
    <postcode>2485 - Tweed Heads</postcode>
    <postcode>2076 - Wahroonga</postcode>
    <postcode>2640 - West Albury</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4066 - Auchenflower</postcode>
    <postcode>4032 - Chermside</postcode>
    <postcode>4214 - Hope Island</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>4224 - Tugun</postcode>
    <postcode>5037 - Kurralta Park</postcode>
    <postcode>3165 - Bentleigh East</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>3677 - Wangaratta</postcode>
    <postcode>3690 - Wodonga</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>West-vlaanderen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Norrebro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Arhus N</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Frederiksberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Oulu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cremona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Meldola (FC)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Orbassano TO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Banska Bystrica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Martin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Nitra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Trnava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Islas Baleares</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Goteborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Malmo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Molnlycke</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Orebro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Surrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Astellas Pharma Inc</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Medivation, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if continued treatment with Enzalutamide is
      effective in patients with metastatic prostate cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01995513</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>